Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $25.24

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $25.24, but opened at $23.80. Calliditas Therapeutics AB (publ) shares last traded at $24.00, with a volume of 4,643 shares changing hands.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CALT. Citigroup raised their price target on shares of Calliditas Therapeutics AB (publ) from $76.00 to $79.00 and gave the company a “buy” rating in a report on Friday, February 24th. Guggenheim began coverage on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, February 28th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $79.00.

Calliditas Therapeutics AB (publ) Stock Up 3.3 %

The business’s fifty day moving average price is $19.40 and its two-hundred day moving average price is $17.22. The firm has a market capitalization of $738.79 million, a P/E ratio of -15.21 and a beta of 1.48. The company has a debt-to-equity ratio of 0.95, a quick ratio of 4.33 and a current ratio of 4.34.

Institutional Trading of Calliditas Therapeutics AB (publ)

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC boosted its stake in Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after purchasing an additional 886 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock worth $51,000 after purchasing an additional 3,112 shares in the last quarter. Optiver Holding B.V. boosted its stake in Calliditas Therapeutics AB (publ) by 1,304.3% in the 3rd quarter. Optiver Holding B.V. now owns 12,625 shares of the company’s stock worth $191,000 after purchasing an additional 11,726 shares in the last quarter. Finally, HBK Sorce Advisory LLC boosted its stake in Calliditas Therapeutics AB (publ) by 100.0% in the 4th quarter. HBK Sorce Advisory LLC now owns 90,000 shares of the company’s stock worth $104,000 after purchasing an additional 45,000 shares in the last quarter. 3.13% of the stock is currently owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.